A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

Trial Details

NCT ID
NCT07462377
Phase
PHASE1
Sponsor
EpiBiologics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • EPI-326
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Lake Success, New York, United States|40.77066,-73.71763
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participant has a life expectancy \> 12 weeks at Day 1.
  • Participant has an ECOG performance status of 0-2.
  • Participant has pathologically confirmed NSCLC or HNSCC.
  • o For NSCLC: the tumor harbors any documented EGFR mutation, insertion, or deletion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →